Extended Data Fig. 4: Viability and cell death of human micro-islets.
From: Targeted pharmacological therapy restores β-cell function for diabetes remission
Measurement of human micro-islet viability and cell death with and without cytokine exposure and in the present of different compounds at the indicated doses. (a) ATP content and (b) Caspase 3/7 activity of human micro-islets. a, N = 6 micro-islets of n = 3 human donors for each condition. Boxplot of all data points. Line indicates the median. #P indicates P-value to vehicle no stress condition. *P indicates P-value to vehicle cytokine exposure. No stress versus cytokines stress by unpaired two-sided t-test (t = 1.756, df = 33). Otherwise one-way ANOVA with donor as random effect followed by Tukey post-hoc (Flow dose(4, 81) = 6.68; Fmedium dose(4, 82) = 10.68; Fhigh dose(4, 81) = 6.30). b, N = 3–4 micro-islets of n = 3 human donors for each condition. Boxplot of all data points. Line indicates the median. #P indicates P-value to vehicle no stress condition. *P indicates P-value to vehicle cytokine exposure. No stress versus cytokines stress by unpaired two-sided t-test (t = 2.567, df = 22). Otherwise one-way ANOVA with donor as random effect followed by Tukey post-hoc (Flow dose(4, 52) = 5.58; Fmedium dose(4, 52) = 4.44; Fhigh dose(4,53) = 4.23).
